NCT04003948View on ClinicalTrials.gov

Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

April 26, 2024

Study Completion Date

April 26, 2024

Conditions
Drug DependenceDrug Use DisordersOpioid Dependence
Interventions
DRUG

Ibogaine Hydrochloride

Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.

Trial Locations (1)

43204

Hospital Universitari Sant Joan, Reus

All Listed Sponsors
collaborator

Multidisciplinary Association for Psychedelic Studies

OTHER

collaborator

University Rovira i Virgili

OTHER

collaborator

Universidad Autonoma de Madrid

OTHER

collaborator

Hospital Universitari Sant Joan de Reus

OTHER

collaborator

University of Sao Paulo

OTHER

lead

International Center for Ethnobotanical Education, Research, and Service

OTHER

NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification | Biotech Hunter | Biotech Hunter